WO2003099761A1 - Process for the manufacture of sertraline - Google Patents
Process for the manufacture of sertraline Download PDFInfo
- Publication number
- WO2003099761A1 WO2003099761A1 PCT/CZ2002/000028 CZ0200028W WO03099761A1 WO 2003099761 A1 WO2003099761 A1 WO 2003099761A1 CZ 0200028 W CZ0200028 W CZ 0200028W WO 03099761 A1 WO03099761 A1 WO 03099761A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dichlorophenyl
- mixture
- process according
- cis
- sertraline
- Prior art date
Links
- HQCPZVQUFULCMY-ZSOXZCCMSA-N C[C@@H](CC1)c2ccccc2C1c(cc1)cc(Cl)c1Cl Chemical compound C[C@@H](CC1)c2ccccc2C1c(cc1)cc(Cl)c1Cl HQCPZVQUFULCMY-ZSOXZCCMSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/24—Preparation of compounds containing amino groups bound to a carbon skeleton by reductive alkylation of ammonia, amines or compounds having groups reducible to amino groups, with carbonyl compounds
- C07C209/28—Preparation of compounds containing amino groups bound to a carbon skeleton by reductive alkylation of ammonia, amines or compounds having groups reducible to amino groups, with carbonyl compounds by reduction with other reducing agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Definitions
- the invention relates to the process for sertraline manufacture by the reductive amination of 4-(3,4-dichlorophenyl)-3,4-dihydro-1-(2H)- naphthalenone in pure separated geometric cis and trans isomers.
- the conversion of trans to cis isomer and the preparation of polymorph of 1S-cis isomer follows.
- Another method describes preparation of aminoxide by reaction of naphthalenone with N-methylhydroxylamine followed by hydrogenation of the reaction product on Raney nickel catalyst (US 6,034,274).
- the catalytic hydrogenation provides a higher yield of cis isomer than reduction in homogeneous phase but requires a special hydrogenation apparatus.
- the contamination of the product by heavy metals may occur.
- the whole procedure is a two-step process with an unstable intermediate and with a rather complicated isolation of the final product.
- N-methyl-N- 1 ,2,3,4-tetrahydro-1-naphthylformamides are hydrolyzed and then isolated as salts from the base by selective crystallization in the presence of acid.
- the reaction is carried out in the temperature range of 150-220 °C.
- the reaction of 1-naphthol with 1 ,2-dichlorobenzene catalyzed by aluminum chloride claimed in the mentioned patent application is not new.
- Hydrolysis of the formamides is carried out at boiling point under reflux in the mixture of Ci - C 8 alcohols with water in alkaline media, e.g. in butanol with potassium hydroxide.
- the catalysis by means of titanium tetrachloride is connected with safety hazard (a storming dissociation in water and aggressive dissociation products).
- safety hazard a storming dissociation in water and aggressive dissociation products.
- the reduction by hydrides increases isolation difficulties resulting in lower yields.
- the asymmetric syntheses of sertraline intermediate are not advantageous being multi-steps with a relatively low final yield and with demand on expensive row materials.
- racemic 4-(3,4-dichlorophenyl)-3,4-dihydro-1-(2H)naphthalenone (I) is manufactured by the method analogous to prior art (see: Zhur. Org. Khimii 18(4), 870-878 (1982), CA 76 #140, 2865 (1972), Houben-Weyl, Vll/2b, 1710), US 5,019,655.
- Salts of metals listed above are added to increase the yield and decrease the content of undesirable reaction products.
- the reductive amination can be carried out alternatively by methylammonium formate in the same media as listed above instead of a mixture of methylammonium chloride or methylammonium sulfate with sodium formate.
- the solvent and salts are extracted with water in one step procedure after the reaction has been completed.
- the product is extracted into chloroform or ethyl acetate.
- the organic layer is washed out with water, dried and evaporated in vacuo.
- the evaporated residue is dissolved in ethanol.
- a half portion of hydrochloric acid (by volume) (1 : 1 , i.e., 5.5M) is added to the solution.
- the mixture is refluxed.
- trans isomer hydrochloride (Mb) remains dissolved whereas cis-isomer hydrochloride (lla) crystallizes from the solution and is washed and dried on the air.
- Ethyl acetate is added to the filtrate evaporated almost to dryness and then it crystallizes under a lowered temperature.
- Yield of the both isomers, cis and trans is 96.5 % whereof the cis isomer fraction contains 98.1 % of cis and 1.8 % of trans isomer.
- the fraction of trans isomer contains 92.5 % of trans and 7.2 % of cis isomer (HPLC), m.p. is the same as given in literature (J. Med. Chem.
- the hydrolysis is carried out in the same step without isolation of the intermediates.
- the isomers lla and lib are readily obtained.
- the purity of lla and lib is 98 % and 92 %, respectively; whereof the amount to 99.6 % represents the other of the two geometric isomers.
- the reductive amination of naphthalenone (I) can be carried out by a mixture of methylammonium formate and triethylammonium formate in N-methylformamide medium under catalysis of salts (M a X b ) listed above.
- the reaction temperature can be reduced at about 20 to 30 °C under these conditions.
- the yield of 1S.4S enantiomer can be increased by the conversion of lib to lla.
- the reductive amination product containing 92 % of trans and 8 % of cis isomer can be converted to base by adding dried triethylamine to the suspension of hydrochloride in tetrahydrofuran. The precipitate of triethylamine hydrochloride is filtered, washed out with tetrahydrofuran and dried.
- Sodium hydride in a form of 60 % oily suspension and a fine powder of tertiary potassium butylate prepared by dissolving potassium in tertiary butanol (with a major part of solvent evaporated) are added to filtrate.
- Tertiary potassium butylate provided the highest yield from all the basic catalysts.
- a flask with the solution fitted with air condenser equipped with by-pass for nitrogen inlet is heated quickly to 50 °C under nitrogen atmosphere and intensive stirring. The reaction does not require 4 to 48 hours for completion at optimum temperature as stated in US 5,082,970. To reach the equilibrium, it takes only 4 to 10 minutes; moreover, to dissolve the catalyst, a short heating to 50 is sufficient.
- the low reaction order ( ⁇ 1) and low activation energy has the consequence that the portion of catalyst and reaction temperature influences the equilibrium only to a small extent.
- tertiary potassium butylate is dissolved and the equilibrium is reached in another five- minutes interval.
- the solution is cooled under nitrogen atmosphere and then 250 ml of water and 50 g of sodium chloride are added. Two layers are formed; the organic layer is evaporated in vacuo. Since tetrahydrofuran has been in contact with a strong alkali at elevated temperature, there is no danger of increasing level of organic peroxides during evaporation.
- Desired 1S,4S enantiomer is separated by means of a known in the art procedure of crystallization with chiral D(-)mandelic acid. Treating the mandelate suspension in ethyl acetate with 10-% sodium hydroxide solution leads to complete dissolution. The layers are separated. The organic layer is dried and evaporated. Obtained colorless oil is stirred with 2-propanol and precipitated in a 1.25 molar excess of 3M 2-propanolic hydrochloric acid. A slow addition of the acid yields a very viscous gel. After two hours of stirring diisopropyl ether is added. Intensive stirring causes a rapid recrystallization.
- Any polymorph can be converted to polymorph Fll in a following way: a dried sertraline hydrochloride is dissolved in threefold (w/v) of N,N- dimethylformamide p. a. at the temperature of 80 - 90 °C. The solution cools spontaneously to 70 °C. Acetone p. a. is slowly added to the mixture under intensive stirring. Precipitated crystals are gelatinous and dense and recrystallize after short stirring. Polymorph is filtered through sinter S3 or S4 and dried at 50 - 60 °C in vacuo.
- the reaction mixture is cooled to 25 °C and poured on ice. 35 ml of hydrochloric acid and 900 ml of chloroform are added. The layers are separated in a separating funnel and the aqueous layer is washed with a small portion of chloroform repeatedly. The organic extracts are combined and washed twice with water and the organic layer is dried over anhydrous sodium sulfate. Chloroform is distilled out under atmospheric pressure. The excess of 1 ,2-dichlorobenzene is distilled out at 100 °C in vacuo. 1 ,2-dichlorobenzene is recuperated and can be used in another batch.
- the ratio of 3,4-dichlorophenyl- and 2,3-dichlorophenylnaphthalenone isomers is determined by HPLC with UV detection. The analysis is carried out on column Zorbax SB C-18, 250 x 4.6 mm under following conditions: mobile phase: methanol-water 67 : 33, flow rate: 1 ml/min, column temperature: 40 °C, wavelength: 230 nm.
- the naphthalenone isomer ratio is calculated from the ratio of peak areas. (Response factors are approximately the same for the both isomers at the applied wavelength).
- Adrien et al. US 5,019,655) declared 98-99 % purity (GC) of naphthalenone (I) obtained under similar conditions.
- 2,3-dichlorophenyl isomer is almost the same.
- the colorless product is undergone the fractional crystallization from ethanol.
- a half of crystalline product is dissolved in a sixfold portion (w/w) of 96-% boiling ethanol and then cooled slowly to crystallize.
- the mixture is inoculated with a small portion of nuclei at temperature of 60 °C and is left stayed for 6 hours, filtered and washed with a small portion of ethanol.
- the second part of crude material is introduced to the mother liquor and recrystallized identically, filtered and washed.
- the both parts of product are combined and dried. The same procedure is carried out twice so that the content of the 2,3-dichlorophenyl isomer has dropped under a critical limit.
- the yield is 86 %, m.p. 102-104 °C. All the mother liquors are combined and evaporated to a quarter of the initial volume. The crystalline material is isolated the next day, filtered and added to another crude charge (the purity of that is similar).
- the mixture is heated to 145 °C and the temperature is kept in the range of 145 -155 °C for 10 hours.
- the reaction can be interrupted by cooling under 100 °C any time and started again by reheating.
- the mixture is cooled down after finishing the reaction.
- the reaction mixture is protected under nitrogen atmosphere until the temperature has dropped below 100 °C.
- the solvent and salts are washed out with approximately 700 ml of water in one step.
- the product is extracted with 700 ml of chloroform and/or ethyl acetate.
- the layers are separated.
- the organic layer is dried over sodium sulfate and evaporated to dryness.
- the evaporated residue is dissolved in 480 ml of ethanol and 240 ml (i.e.
- the yield is 57 g of cis isomer and 62.5 g of trans isomer as hydroch rides (i.e. 96.5 %).
- Cis isomer fraction contains 98.1 % of cis and 1.8 % of trans isomer.
- Trans isomer fraction contains 92.5 % of trans and 7.2 % of cis isomer (HPLC), m.p. are the same as in the literature (J. Med. Chem. 1984, 27, 1508-1515).
- 60 g of mixed product of (lla) and (lib) (the content of 92 % of trans isomer and 8 % of cis isomer) from the reductive amination is converted to base as follows: 30 ml triethylamine (dried over molecular sieve A3) is added to the suspension of hydrochlorides in 500 ml of tetrahydrofuran and is stirred for 0.5 - 1 hour. The suspension is filtered and washed twice with a small portion of tetrahydrofuran. 3.8 g of sodium hydride (in a form of 60 % of solid in mineral oil suspension) and 18 g of fine powdered potassium tert- butylate is added to the filtrate.
- Potassium tert-butylate is prepared by dissolving potassium in tert-butanol and evaporating the solvent (it still contains approximately 25-30 % of tert-butanol).
- the reaction flask is connected to reflux with by-pass for nitrogen inlet and heated quickly to 50 °C under intensive stirring under nitrogen atmosphere.
- Within five minutes potassium tert-butylate is dissolved almost completely and the equilibrium is reached in the next five minutes.
- the solution is cooled freely under nitrogen atmosphere. 250 ml of water and 50 ml of saturated aqueous sodium chloride solution is added. The layers are separated and the organic layer is evaporated to dryness.
- Example 7 The cis isomer (60 %, i.e., 36 g) is recrystallized as given in Example 4 and the product is combined with cis isomer obtained from the synthesis.
- the mother liquor with 40 % of trans isomer has the same concentration as the original one. They are combined and reused in another charge.
- the crystalline mandelate is filtered off, washed with a small portion of diethyl ether and dried on the air (the yield is 16 g, m. p. 187-189 °C).
- Mandelate is converted to base by similar work up as racemic hydrochloride (lla). Only 200 ml of 2.5M sodium hydroxide and 500 ml of ethyl acetate are used. The organic layer is dried and evaporated. The product is dissolved in 2-propanol and precipitated with gaseous hydrogen chloride. The excess of hydrogen chloride is stripped by nitrogen. The resulting pH is to be 2 (universal indicator paper). The isolated compact gel has been stirred for 2 hours.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002485499A CA2485499A1 (en) | 2002-05-10 | 2002-05-10 | Process for the manufacture of sertraline |
HU0500215A HUP0500215A2 (en) | 2002-05-10 | 2002-05-10 | Process for the manufacture of sertraline |
AU2002311059A AU2002311059A1 (en) | 2002-05-10 | 2002-05-10 | Process for the manufacture of sertraline |
EP02734991A EP1503978A1 (en) | 2002-05-10 | 2002-05-10 | Process for the manufacture of sertraline |
PCT/CZ2002/000028 WO2003099761A1 (en) | 2002-05-10 | 2002-05-10 | Process for the manufacture of sertraline |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CZ2002/000028 WO2003099761A1 (en) | 2002-05-10 | 2002-05-10 | Process for the manufacture of sertraline |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003099761A1 true WO2003099761A1 (en) | 2003-12-04 |
Family
ID=29555563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CZ2002/000028 WO2003099761A1 (en) | 2002-05-10 | 2002-05-10 | Process for the manufacture of sertraline |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1503978A1 (en) |
AU (1) | AU2002311059A1 (en) |
CA (1) | CA2485499A1 (en) |
HU (1) | HUP0500215A2 (en) |
WO (1) | WO2003099761A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006129324A2 (en) | 2005-06-03 | 2006-12-07 | Hetero Drugs Limited | A highly stereoselective synthesis of sertraline |
US7253320B2 (en) | 2005-04-07 | 2007-08-07 | Sandoz Ag | Process for preparing polymorphic form II of sertraline hydrochloride |
WO2007119247A2 (en) * | 2006-04-17 | 2007-10-25 | Unichem Laboratories Limited | Improved manufacturing procedure for the preparation of polymorphic form ii of cis-(1s)-n-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthleneamine hydrochloride (sertraline hydrochloride) |
CN104876812A (en) * | 2015-05-20 | 2015-09-02 | 浙江华海药业股份有限公司 | Method for preparing sertraline hydrochloride intermediate and impurity |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4855500A (en) * | 1988-05-04 | 1989-08-08 | Pfizer Inc. | Process for preparing a ketimine |
EP0947499A2 (en) * | 1998-04-01 | 1999-10-06 | Catalys | Process for the preparation of racemic sertraline |
WO1999057095A2 (en) * | 1998-05-05 | 1999-11-11 | EGIS Gyógyszergyár Rt. | Process for the preparation of a pharmaceutical intermediate |
EP1059287A1 (en) * | 1999-06-09 | 2000-12-13 | Pfizer Products Inc. | Process for preparing sertraline from chiral tetralone |
-
2002
- 2002-05-10 CA CA002485499A patent/CA2485499A1/en not_active Abandoned
- 2002-05-10 AU AU2002311059A patent/AU2002311059A1/en not_active Abandoned
- 2002-05-10 HU HU0500215A patent/HUP0500215A2/en unknown
- 2002-05-10 EP EP02734991A patent/EP1503978A1/en not_active Withdrawn
- 2002-05-10 WO PCT/CZ2002/000028 patent/WO2003099761A1/en not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4855500A (en) * | 1988-05-04 | 1989-08-08 | Pfizer Inc. | Process for preparing a ketimine |
EP0947499A2 (en) * | 1998-04-01 | 1999-10-06 | Catalys | Process for the preparation of racemic sertraline |
WO1999057095A2 (en) * | 1998-05-05 | 1999-11-11 | EGIS Gyógyszergyár Rt. | Process for the preparation of a pharmaceutical intermediate |
EP1059287A1 (en) * | 1999-06-09 | 2000-12-13 | Pfizer Products Inc. | Process for preparing sertraline from chiral tetralone |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7253320B2 (en) | 2005-04-07 | 2007-08-07 | Sandoz Ag | Process for preparing polymorphic form II of sertraline hydrochloride |
WO2006129324A2 (en) | 2005-06-03 | 2006-12-07 | Hetero Drugs Limited | A highly stereoselective synthesis of sertraline |
WO2007119247A2 (en) * | 2006-04-17 | 2007-10-25 | Unichem Laboratories Limited | Improved manufacturing procedure for the preparation of polymorphic form ii of cis-(1s)-n-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthleneamine hydrochloride (sertraline hydrochloride) |
WO2007119247A3 (en) * | 2006-04-17 | 2009-05-14 | Unichem Lab Ltd | Improved manufacturing procedure for the preparation of polymorphic form ii of cis-(1s)-n-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthleneamine hydrochloride (sertraline hydrochloride) |
CN104876812A (en) * | 2015-05-20 | 2015-09-02 | 浙江华海药业股份有限公司 | Method for preparing sertraline hydrochloride intermediate and impurity |
CN104876812B (en) * | 2015-05-20 | 2020-12-08 | 浙江华海药业股份有限公司 | Process for preparing sertraline hydrochloride intermediates and impurities |
Also Published As
Publication number | Publication date |
---|---|
AU2002311059A1 (en) | 2003-12-12 |
CA2485499A1 (en) | 2003-12-04 |
EP1503978A1 (en) | 2005-02-09 |
HUP0500215A2 (en) | 2005-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2403823B1 (en) | Process for the preparation of cinacalcet and salts thereof, and intermediates for use in the process | |
CN1216033C (en) | Process for cis-selective catalytic hydrogenation of sub cyclohexylidenamines | |
US6232500B1 (en) | Process for preparing a ketimine | |
ITMI20010011A1 (en) | PROCESS TO CONVERT SERTRALINA STEREOIOSOMERS TO SERTRALINA | |
HU226424B1 (en) | Process for producing enantiomer mixture for preparation of sertraline | |
US5616799A (en) | Process for the preparation of glycoloylanilides | |
IL141690A (en) | Process for preparation of rasagiline and its salts | |
WO2001016089A1 (en) | A process for the preparation of cis-(1s,4s)-n-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthaleneamine hydrochloride | |
EP1503978A1 (en) | Process for the manufacture of sertraline | |
US6900355B2 (en) | Process for the cis-selective catalytic hydrogenation of cyclohexylidenamines | |
US6958418B2 (en) | Process for preparing vanillylamine hydrochloride | |
TW201130785A (en) | Process for preparing 2,2-difluoroethylamine by hydrogenating 1,1-difluoro-2-nitroethane | |
CZ292770B6 (en) | Process for preparing sertraline | |
US6723878B2 (en) | Method for preparing sertraline | |
JP2008007489A (en) | Method for manufacturing optically active 1-(fluoro, trifluoromethyl or trifluoromethoxy-substituted phenyl)alkylamine n-monoalkyl derivative | |
WO2012098044A1 (en) | Process for the preparation of n,n-diisopropyl-3-(2-hydroxy-5-methylphenyl)- 3-phenyl propylamine and its salts starting from a novel intermediate | |
CA2461574C (en) | Process for preparing vanillylamine hyrochloride | |
WO2010076763A2 (en) | An improved process for the manufacture of sertraline | |
US20070260090A1 (en) | Highly Steroselective Synthesis of Sertraline | |
EP2476665A1 (en) | Process for the preparation of N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)- 3-phenyl propylamine and its salts starting from a novel intermediate | |
MXPA00006986A (en) | Novel process for preparing a ketimine | |
HU191927B (en) | Process for production of amino-cis-2,6-lupeditin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BG BY CA CH CN DE DK EE ES FI GB HR HU IL IN JP NO PL PT RO RU SE SI SK TR UA US YU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002734991 Country of ref document: EP Ref document number: 2485499 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 108940 Country of ref document: BG Ref document number: 10894002 Country of ref document: BG |
|
WWP | Wipo information: published in national office |
Ref document number: 2002734991 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002734991 Country of ref document: EP |